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Drug resistance by overexpression of ATP-binding cassette (ABC) transporters is an impediment in the
treatment of leishmaniasis. Flavonoids are known to reverse multidrug resistance (MDR) in Leishmania and
mammalian cancers by inhibiting ABC transporters. Here, we found that synthetic flavonoid dimers with three
(compound 9c) or four (compound 9d) ethylene glycol units exhibited a significantly higher reversing activity
than other shorter or longer ethylene glycol-ligated dimers, with 3-fold sensitization of pentamidine and
sodium stibogluconate (SSG) resistance in Leishmania, respectively. This modulatory effect was dosage de-
pendent and not observed in apigenin monomers with the linker, suggesting that the modulatory effect is due
to its bivalent nature. The mechanism of reversal activity was due to increased intracellular accumulation of
pentamidine and total antimony in Leishmania. Compared to other MDR modulators such as verapamil,
reserpine, quinine, quinacrine, and quinidine, compounds 9c and 9d were the only agents that can reverse SSG
resistance. In terms of reversing pentamidine resistance, 9c and 9d have activities comparable to those of
reserpine and quinacrine. Modulators 9c and 9d exhibited reversal activity on pentamidine resistance among
LeMDR1/, LeMDR1/, and LeMDR1-overexpressed mutants, suggesting that these modulators are specific
to a non-LeMDR1 pentamidine transporter. The LeMDR1 copy number is inversely related to pentamidine
resistance, suggesting that it might be involved in importing pentamidine into the mitochondria. In summary,
bivalency could be a useful strategy for the development of more potent ABC transporter modulators and
flavonoid dimers represent a promising reversal agent for overcoming pentamidine and SSG resistance in
parasite Leishmania.
Leishmaniasis, one of the six major parasitic diseases tar-
geted by the World Health Organization (WHO), is endemic
in 88 countries around the world. Most leishmaniasis occurs in
northern Africa, Asia, Latin America, and the Middle East.
There are 350 million people at risk of infection, with 2 million
cases annually. About a quarter of these cases are visceral
leishmaniasis, which is the lethal form if left untreated (1). The
primary treatment of leishmaniasis is by the administration of
pentavalent antimonials (Pentostam and Glucantime). Sec-
ondary treatment includes pentamidine and amphotericin B.
These treatments have many side effects, and their efficacies
are further impeded by the emergence of clinical resistance to
some of these antileishmanials (5). It has been reported that
more than 50% of the visceral leishmaniasis cases in India are
resistant to the antimonials (43). The WHO has stated that the
resistance to pentavalent antimonials in Leishmania is one of
its top priorities (6). Newer treatments such as miltefosine, a
hexadecylphosphocholine, has also shown tremendous prom-
ise. However, due to the long half-life in blood, treatment with
miltefosine can easily lead to drug resistance.
ATP-binding cassette (ABC) transporters are characterized
by the presence of the highly conserved ATP-binding domains.
ABC transporters were first described in multidrug-resistant
(MDR) cancer cells where P-glycoprotein (P-gp), a gene prod-
uct of MDR1 (ABCB1), functioned as an ATP-dependent drug
efflux pump to extrude a variety of hydrophobic drugs from the
cancer cells, hence reducing the intracellular drug accumula-
tion (26). Later on, the multidrug resistance-associated protein
(MRP1 encoded by ABCC1) was found to be another ABC
transporter that can also mediate the efflux of drugs and causes
MDR (47). Both P-gp and MRP consist of two homologous
halves, each composed of a transmembrane domain (TMD),
involved in drug binding and efflux, and a cytosolic nucleotide-
binding domain (NBD), with characteristic Walker A and B
motifs involved in ATP binding and hydrolysis (45). Hydrolysis
of ATP is tightly coupled to drug efflux. Recent evidence has
shown that some P-gp (9, 11, 21, 23) and MRP (34, 35) trans-
porters are involved in drug resistance in the protozoan para-
site Leishmania (38). Resistance to pentavalent antimonials
such as sodium stibogluconate (SSG) in Leishmania tarentolae
is due to an MRP member (LtPGPA). LtPGPA may confer
resistance to antimonials in promastigote cells by sequestration
of the metal-thiol conjugates in an intracellular organelle lo-
cated close to the flagellar pocket (30). Pentamidine is a sec-
ond-line antileishmanial whose mode of action and resistance
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is not well understood. It has been reported that pentamidine
resistance may be due to the exclusion of pentamidine from its
target, mitochondria (4). Recently, a pentamidine resistance
gene (PENr), encoding a protein termed pentamidine resis-
tance protein 1 (PRP1), has been described (12). It is also an
ABC transporter and exhibited a high similarity to members of
the MRP-like family (ca. 30 to 40%) (12). Resistance to milte-
fosine has also been suggested to be due to increased drug
efflux mediated by L. tropica MDR1 (37).
Flavonoids constitute a group of interesting polyphenolic
compounds with a wide distribution in fruits and vegetables
(27, 28) and have been shown to exert a wide range of bene-
ficial effects on human health, including protection against
cardiovascular diseases and different forms of cancers (18). In
the past decade, some flavonoids have been implicated in the
modulation of P-gp-type MDR in cancers and shown to inhibit
a variety of ATP-binding proteins such as plasma membrane
ATPase (24, 44), cyclic AMP-dependent protein kinase (25),
and protein kinase C (17). It is thought that the modulating
activity of the flavonoids arises from competitive binding to the
NBDs of P-gp through their ability to mimic the adenine moi-
ety of ATP. On the other hand, it has been suggested that some
alkyl substituted flavonoids with increased hydrophobic inter-
actions may inhibit MDR through binding with both the ste-
roid-interacting region and the drug binding site of TMDs in
P-gp. In addition, flavonoids have also been demonstrated to
inhibit daunomycin efflux and resensitize L. tropica to dauno-
mycin by binding to the NBD of the P-gp-like transporter (36).
Therefore, flavonoids that are consumed daily and without any
detrimental side effects are attractive targets for development
of novel modulators of MDR to treat both protozoan parasite
Leishmania and cancers.
Recently, an attempt to modulate the activity of P-gp
through the use of polyvalent interaction has been reported
(42). Functional derivatives of stipiamide were linked via eth-
ylene glycol chains of various lengths. It was found that poly-
valency could be a useful strategy to develop more potent P-gp
modulators. Using a similar strategy, we recently reported the
synthesis of a series of novel bivalent flavonoid dimers based
on apigenin linked by various number of ethylene glycol units
(Fig. 1) (8). Apigenin was used because it is a moderate mod-
ulator of MDR in breast cancer cells (48) and has displayed a
moderate affinity for the NBD2 (14). We hypothesized that a
dimer will cooperatively increase the efficacy of apigenin in
binding to NBD, thereby inactivating P-gp. However, without
the crystal structure of the P-gp, the distance between the two
NBD is unknown, even though a model has been constructed
with the two NBD at a distance of about 600 nm apart (31). On
the other hand, it is known that the two NBD sites move closer
upon binding with ligands (41). We therefore synthesized a
whole series of flavonoid dimers with various linker lengths for
screening purpose. These synthetic flavonoid dimers showed a
linker length-dependent inhibition of the P-gp activity in a
MDR breast cancer cell line and in a resistant leukemia cell
line (8). We found that compound 9d was the most potent in
reversing paclitaxel resistance in a breast cancer cell line
(LCC6MDR) (8).
In view of the association between P-gp expression and SSG
and pentamidine resistance in Leishmania reported by others,
we hypothesize that our synthetic apigenin dimers will also
FIG. 1. Structures of flavonoid dimers, flavonoid monomers with ethylene glycol linker and apigenin. The “n” is the number of ethylene glycol
units present in the linker of the flavonoid dimers (9a to 9k-1). The “av” is the average number of ethylene glycol units used during flavonoid dimer
synthesis. The “x” in 10a and 10b is the number of ethylene glycol units added to the flavonoid monomers (10a and 10b). 10a and 10b were used
as controls. The synthesis of these compounds have been reported previously (8).
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have similar modulating effect on the SSG and pentamidine
resistance in Leishmania. In this report, we will demonstrate
that the flavonoid dimers also have a length-dependent MDR-
modulating activity in three Leishmania cells that are resistant
to pentamidine and SSG.
MATERIALS AND METHODS
Cell lines and cell culture. Promastigotes of Leishmania enriettii (LePentR50,
Le wild type, LeMDR1/, and LeMDR1-overexpressed LeV160 mutants) and
Leishmania donovani (LdAG83, Ld2001, and Ld39) were used in the present
study. The former is a natural infective strain of guinea pig, and the latter is a
clinical strain, which may cause visceral leishmaniasis in humans. Both strains
were cultured in Schneider’s Drosophila medium (pH 6.9; Invitrogen) supple-
mented with 10% (vol/vol) heat-inactivated fetal calf serum (HyClone) with 4
mM glutamine (Sigma) and 25-g/ml gentamicin solution (Invitrogen) at 27°C
for 4 days (11).
Promastigotes of LePentR50 (pentamidine resistant, 50% inhibitory concen-
tration [IC50] of pentamidine  117 g/ml), Ld2001 (SSG resistant, IC50 of
SSG  4.1 mg/ml), and Ld39 (SSG resistant, IC50 of SSG  6.4 mg/ml) were
cultured in the presence of 50 g of pentamidine (Sigma)/ml and 3.5 mg of SSG
(a gift from Glaxo SmithKline)/ml, respectively. No SSG was added to the L.
donovani wild type (LdAG83, IC50 of SSG  2.4 mg/ml). Promastigotes of
LeV160 were cultured in the presence of 160 g of vinblastine/ml. No pentam-
idine and vinblastine (Sigma) was added to the Le wild type and the LeMDR1/
mutant.
Amastigotes of L. donovani were prepared by spinning down 50 ml of 4-day-
old promastigotes (late log phase) and transferring them to an axenic medium
containing M199 medium (Gibco), 0.5% Trypto casein soya, 3 mM L-cysteine, 15
mM D-glucose, 5 mM L-glutamine, 4 mM NaHCO3, 25 mM HEPES, 0.01 mM
bathocuproine-disulfonic acid, and 0.023 mM hemin. Cells were then incubated
at 37°C for 24 h. Amastigotes became ovoid in shape and were ready for drug
accumulation assay.
Cell viability assay. The viability of promastigotes was determined by the Cell
Titer 96 aqueous assay (Promega), which uses a novel tetrazolium compound
(MTS) and electron coupling reagent, phenazine methosulfate (PMS). Promas-
tigotes were seeded into 96-well flat bottom microtiter plate at 105 cells per well
in a final volume of 100 l of medium. For determining the cytotoxic effect of
flavonoid dimers to the parasites, various concentrations of flavonoid dimers
were added to the promastigotes. For determining the reversal effect of flavonoid
dimers with different spacer lengths, various concentrations of antileishmanial
drugs, either pentamidine or SSG, vinblastine, and puromycin was added to the
wells with or without flavonoid dimers. The parasites were incubated at 27°C for
72 h. Each concentration of antileishmanials with or without synthetic modula-
tors was tested in triplicates in each experiment. We mixed 2 mg of MTS/ml and
0.92 mg of PMS/ml in an MTS/PMS ratio of 20:1. After 72 h of incubation, 10 l
of MTS-PMS mixture was added into each well of microtiter plate. The plate was
then incubated at 27°C for 4 h for color development. After 4 h of incubation, the
optical density values were determined at 490 nm by using an automatic micro-
titer plate reader (Bio-Rad). The results were presented as a percentage of the
survivors (the optical density value of each well with a test compound is divided
by the value for an untreated control well).
Pentamidine accumulation assay by HPLC. The effect of flavonoid dimers on
accumulation of pentamidine was investigated. Portions (1 ml) of 4-day-old
promastigotes (late log phase with a cell density of about 2  108 cells/ml) were
incubated with 0.84 mM pentamidine and various concentrations of flavonoid
dimer (9d), including 0, 15, 30, and 60 M, at 27°C for 3 h in the dark. Each
concentration of 9d was tested in triplicates, and this was repeated twice in
separate experiments. After 3 h of incubation, the parasites were washed thrice
with cold phosphate-buffered saline (PBS; pH 7.4). The cell pellet was then
dissolved in 350 l of 75% acetonitrile and lysed by repeated freeze-thaw cycles.
After lysing, the lysed cell suspension was centrifuged at 14,000  g at 4°C for 10
min. The supernatant was collected and ready for determining the pentamidine
concentration by using high-pressure liquid chromatography (HPLC; Agilent
1100 Series) (4). The pentamidine pools were analyzed on Zorbax ODS C18
column (4.6 mm by 25 cm, 5 m) kept at 40°C. The mobile phase consisted of
water (10 mM tetramethylammonium chloride [TMAC], 10 mM sodium hep-
tanesulfonate [SHS], 4.2 mM phosphoric acid [PA]) for pump A and 75%
acetonitrile (ACN) in water (10 mM TMAC, 10 mM SHS, 4.2 mM PA) for pump
B. The column was equilibrated at 40°C overnight before analyses. Using a flow
rate of 1.0 ml/min and signal at 265 nm, analyses were made at 58% pump A and
42% pump B. The retention time of pentamidine is 3.2 min. Compound 9d would
not be eluted out under these conditions. To generate a standard curve, a 200
M stock solution of pentamidine isethionate salt were prepared by dissolving
2.5 mg of pentamidine isethionate salt in 21 ml of 75% ACN (10 mM TMAC, 10
mM SHS, 4.2 mM PA). Concentrations of 100, 50, 25, and 13 M were then
made by serial dilution, allowing the generation of standard curve.
Total antimony [Sb(III) and Sb(V)] accumulation assay using ICP-MS. The
effect of flavonoid dimers on accumulation of antimony SSG was investigated.
Amastigotes are more susceptible to SSG and therefore accumulate more SSG
compared to promastigotes. We therefore chose to use amastigotes to study the
Sb accumulation assay. A 1-ml portion of 4-day-old amastigotes (2  108 cells/
ml) was incubated with 0.05 mM SSG and various concentrations of flavonoid
dimer (9d), including 0, 30, and 60 M, at 37°C for 3 h. Each concentration of
9d was tested in triplicates, and this was repeated twice in separate experiments.
After 3 h of incubation, the parasites were washed three times with cold PBS (pH
7.4). The cell pellet was dissolved in 200 l of concentrated nitric acid for 24 h
at room temperature. The sample was diluted to 3 ml with distilled water,
resulting in a final concentration of about 5 ppb of total Sb solution. It was then
injected to inductively coupled plasma mass spectrometry (ICP-MS; Perkin-
Elmer) for quantitation. Antimony was measured at its m/z ratios of 121 and 123
with indium (In, m/z  115) as an internal standard. All chemicals used for the
pretreatment of the samples were of at least analytical grade, and the distilled
water was used directly as received without further purification (6).
RESULTS
Pentamidine-resistant L. enriettii (LePentR50) and SSG-re-
sistant L. donovani (Ld39 and Ld2001). We used here three
drug-resistant Leishmania cell lines, namely, LePentR50 (pent-
amidine-resistant L. enriettii), Ld39, and Ld2001 (SSG-resis-
tant L. donovani) to study the drug resistance-modulating ac-
tivity of the synthetic flavonoid dimers. LePentR50 is a
pentamidine-resistant L. enriettii cell line obtained by stepwise
selection in our laboratory (unpublished data). It is maintained
in the presence of 50 g of pentamidine/ml and has an IC50 of
about 117 g/ml, whereas the wild-type L. enriettii (Le) has an
IC50 of about 8.7 g/ml (Fig. 2A). Ld39 and Ld2001 are two L.
donovani cell lines that are resistant to the pentavalent anti-
monial SSG (2). Ld39 and Ld2001 are maintained in the pres-
ence of 3.5 mg SSG/ml and have IC50s of 6.1 and 4.1 mg/ml,
respectively, whereas the wild-type L. donovani (LdAG83) has
an IC50 of about 2.4 mg/ml (Fig. 2B).
In vitro cytotoxicity of synthetic flavonoid dimers to Leish-
mania parasites. The structure of the synthetic flavonoid
dimers is shown in Fig. 1. The synthesis, structural character-
ization, and numbering scheme of these flavonoid dimers have
been reported elsewhere (8). Briefly, these flavonoid dimers
are made up of two apigenin monomers linked by a biocom-
patible ethylene glycol linker with a different number of units
(denoted by “n”). Compounds 9a to 9k-1 have n values equal
to 1 to 13. We have previously suggested that each apigenin
moiety of these flavonoid dimers will bind to P-gp, thereby
inhibiting the pump activity (8). Compounds 10a and 10b are
apigenin monomers with 3 and 4 units of ethylene glycol only.
The cytotoxicity of synthetic flavonoid dimers in each Leish-
mania cell line was measured by the MTS-based cell prolifer-
ation method. Table 1 summarizes the IC50 value of each
synthetic modulator for LePentR50, LdAG83, and L39. Pent-
amidine-resistant LePentR50 was relatively resistant to syn-
thetic flavonoid dimers (9a to 9f and 10a and 10b), with IC50
values ranging from 40 M to greater than 200 M. The
sensitivity of L. donovani LdAG83 and Ld39 to synthetic fla-
vonoid dimers was comparable to that of L. enriettii except for
compounds 9c and 9d. It was found that both LdAG83 (IC50 of
9c 8 0.3 M and IC50 of 9d 7 0.4 M) and Ld39 (IC50
932 WONG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
of 9c 11 0.7 M and IC50 of 9d 10 0.9 M) were more
susceptible to 9c and 9d than was LePentR50. The species
difference between L. enriettii and L. donovani was limited to
the apigenin dimers 9c and 9d only. These two species were
equally sensitive to apigenin monomer and apigenin with three
(10a) or four (10b) ethylene glycol units (Table 1). The hyper-
sensitivity of L. donovani, both LdAG83 and Ld39, to com-
pounds 9c and 9d may mean that these two apigenin dimers
may be useful as an anti-L. donovani agent. Indeed, we have
previously demonstrated that 5 M concentrations of 9c and
9d were nontoxic to mammalian cancer cells in vitro (8). In the
studies described below, we used 6 M concentrations of syn-
thetic flavonoid dimers to test their modulating effect on the
drug resistance in LePentR50, Ld39, and Ld2001.
Effect of synthetic flavonoid dimers on modulating pentam-
idine resistance of LePentR50. Dimethyl sulfoxide (DMSO)-
treated LePentR50 has an IC50 of pentamidine of about
117.0 3.0 g/ml (Fig. 3A). A 6 M concentration of com-
pound 9c (n  3; IC50  40.0  2.7 g/ml; P  0.01) and of 9d
(n  4; IC50  39.2  2.1 g/ml; P  0.01) significantly
reduced the IC50 of LePentR50 by 3-fold (Fig. 3A). Other
flavonoid dimers with either shorter linker lengths (9a [IC50 
90  4.88 g/ml] and 9b [IC50  89.2  8.92 g/ml]) or longer
linker lengths (9e [IC50  90  7.88 g/ml], 9f [IC50  75 
10.99 g/ml], 9 h-1 [IC50  106  2.7 g/ml], 9i [IC50  73 
3.54 g/ml], 9j [IC50  134  5.4 g/ml], and 9k-1 [IC50 
130 6.1 g/ml]) gave less than half or no modulating activity
(Fig. 3A). The “U”-shaped relationship between the linker
length and modulating activity of the flavonoid dimers suggests
that the targets of the apigenin moiety are separated by a
relatively defined distance. The control compounds of apigenin
monomer with three or four ethylene glycol units (10a and
10b) did not give any modulating activity even when used at
double the concentration (12 M) (Fig. 3A; IC50 100.0 5.0
g/ml and 98.5  8.5 g/ml, respectively). This suggests that
the modulating activity of compounds 9c and 9d is indeed due
to their dimeric nature. A simple molar increase in the number
of apigenin moiety did not result in any significant modulating
activity. As a control, the linkers with n  3 and 4 (Tri-PEG-
linker and Tetra-PEG linker) did not have any reversing effect
(Fig. 3A).
Effect of synthetic flavonoid dimers on modulating the SSG
resistance of Ld39 and Ld2001. We have also measured the
effect of synthetic flavonoid dimers on modulating SSG resis-
tance of Ld39 and Ld2001 promastigotes. Among the synthetic
flavonoid dimers (used at 6 M), 9c and 9d were the most
effective in modulating the SSG resistance of L. donovani Ld39
promastigotes. The IC50 of SSG of Ld39 was reduced from
6.4 0.7 mg/ml (DMSO treated) to 2.3  0.2 mg/ml (9c
treated) and 2.3  0.3 mg/ml (9d treated) (Fig. 3B). Similar to
the pentamidine resistance in LePentR50, compounds with
shorter linkers (9a and 9b) or longer linkers 9e to 9k-1) did not
show any significant SSG resistance modulating activity (Fig.
3B). Apigenin, 10a, and 10b, even when used at double the
concentration (12 M), also did not show any significant mod-
ulating activity (Fig. 3B). The control linkers with n  3 (Tri-
TABLE 1. IC50 of synthetic flavonoids for Leishmania parasites
Compound
Mean IC50 (M)  SDa
LePentR50 LdAG83 Ld39
9a 	200 95 3.2 117 10
9b 	200 	200 	200
9c 	200 8 0.3 11 0.7
9d 	200 7 0.4 10 0.9
9e 70  3.0 30  1.2 42 2.3
9f 40  5.3 11  2.0 13 0.6
9h-1 ND 12 0.2 14 0.1
9i ND 10 0.3 14 0.1
9j ND 	200 	200
9k-1 ND 50 7 60 3
10a 	200 	200 	200
10b 	200 	200 	200
Apigenin 55  2.6 32  4.1 43 5.9
a The IC50 values of each synthetic flavone were determined by an MTS-based
proliferation assay. Each IC50 value was derived from at least two independent
experiments with triplicates in each experiment. A value of “	200” indicates that
an IC50 value could not be determined because these modulators did not have
any cytotoxic effect at the highest concentration tested (200 M). ND, IC50
values were not determined for these modulators but no cytotoxic effect was
observed at 12 M, which was twice the concentration used to study drug
resistance modulating activity.
FIG. 2. Drug-resistant Leishmania used in the present study: pent-
amidine-resistant L. enriettii (LePentR50) and SSG-resistant L. dono-
vani (Ld39 and Ld2001). (A) LePentR50 was a pentamidine-resistant
promastigote cell line selected from wild-type L. enriettii (Le) by grad-
ually increasing the pentamidine concentration in the culture medium
to 50 g/ml. (B) Ld39 and Ld2001 were L. donovani clinical isolates
known to be resistant to SSG. Wild type L. enriettii (Le) and L.
donovani (LdAG83) were included for comparison. Percentage survi-
vor was determined by MTS essay.
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PEG-linker) or n  4 (Tetra-PEG-linker) did not demonstrate
any effect as well (Fig. 3B).
Essentially, a similar pattern was observed when the other
SSG-resistant L. donovani strain Ld2001 was studied (Fig. 3C).
Compounds 9c and 9d were the most effective and can de-
crease the IC50 of SSG of Ld2001 from 6.6 mg/ml (DMSO
control) to 1.5 mg/ml (9c) and 1.0 mg/ml (9d), respectively
(Fig. 3C).
Interestingly, all synthetic flavonoid modulators, including
9c and 9d, had no modulatory effect on SSG-sensitive wild-type
L. donovani LdAG83. The IC50 values remained almost the
same with or without any modulators (Fig. 3D). This suggests
that 9c and 9d specifically target a protein that is uniquely or
sufficiently present in SSG-resistant parasite but absent or
rarely expressed in SSG-sensitive parasite.
Synthetic flavonoid dimers 9c and 9d show a dose-depen-
dent modulating activity on pentamidine resistance and accu-
mulation in LePentR50. We have studied the dosage effect of
the two most effective modulators, namely, 9c (containing three
ethylene glycol units) and 9d (containing four ethylene glycol
units) on modulating the pentamidine resistance of LePentR50.
When treated with only 60 g of pentamidine/ml, the survival of
LePentR50 was only slightly decreased (94.0%  2.3% of un-
treated). Cotreatment of 60 g of pentamidine/ml with in-
creasing concentrations of 9c, however, resulted in a gradual
FIG. 3. Modulation of drug resistance by synthetic flavonoid dimers
with different ethylene glycol lengths. The modulating activity of syn-
thetic flavonoid dimers with different lengths of ethylene glycol units
(from one to thirteen units) on the resistance of pentamidine-resistant
L. enriettii LePentR50 (A), SSG resistance of SSG-resistant L. dono-
vani Ld39 and Ld2001 (B and C), and wild-type L. donovani LdAG83
(D) was studied. The IC50 (that is, the concentration of pentamidine or
SSG that can reduce the survival to 50% of the untreated control) was
determined by MTS essay (mean  standard error mean). Promasti-
gotes were seeded at 105 cells per well and incubated at 27°C for 72 h
with various concentrations of pentamidine or SSG in the presence of
DMSO solvent control or various modulators. The modulators used
included flavonoid dimers (9a to 9k-1), monomers (apigenin and
apigenin with three or four ethylene glycol units added), and 10a and
10b (refer to Fig. 1 for structures). Tri-PEG-linker and Tetra-PEG-
linker are linkers with three or four ethylene glycol units. The asterisk
in panels A and B indicates that the differences between the IC50s of
the DMSO control and 9c and 9d are statistically significant (Student
t test; P  0.01).
934 WONG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
decrease in the survival of LePentR50, suggesting that 9c can
modulate the pentamidine resistance of LePentR50 in a dose-
dependent manner (Fig. 4A). The EC50 for 9c (the effective
concentration of 9c that results in 50% survival of LePentR50
at 60 g of pentamidine/ml) is about 1.85 M. A similar ob-
servation was made for compound 9d (Fig. 4B). No toxicity was
observed for 9d up to a concentration of 6 M. The EC50 for
9d is about 0.94 M. Compound 9d is therefore about twice as
effective as 9c in modulating the pentamidine resistance of
LePentR50.
We investigated the effect of 9d on the pentamidine accu-
mulation of LePentR50. Here we have used higher concentra-
tions of 9d (15, 30, and 60 M), together with a shorter incu-
bation time (3 h), to measure the pentamidine accumulation.
Compound 9d can increase the pentamidine accumulation of
LePentR50 in a dose-dependent manner (Fig. 5). The intra-
cellular pentamidine concentration of LePentR50 was gradu-
ally increased from 2.0  0.2 to 2.95  0.01, 4.69  0.51, and
26.6  0.6 M pentamidine/mg of protein when the concen-
tration of 9d was increased from 0 to 15, 30, and 60 M,
respectively (Fig. 5). This result suggests that 9d is modulating
the pentamidine resistance of LePentR40 by increasing the
pentamidine accumulation. Incubation of LePentR50 with 60
M 9d for 3 h did not result in any cytotoxicity (data not
shown). Therefore, the dose-dependent increase in pentami-
dine accumulation is really due to the modulatory effect of 9d
and not to its cytotoxic effect on LePentR50.
Synthetic flavonoid dimers 9c and 9d show a dose-depen-
dent modulating activity on SSG resistance and accumulation
in Ld39 cells. Similar to LePentR50, both 9c and 9d showed a
dose-dependent modulating effect on the SSG resistance of
Ld39 promastigotes (Fig. 6A and B). A 4 M concentration of
9c or 9d can reduce the SSG resistance level of Ld39 back to
the level of the sensitive strain of LdAG83 (Fig. 6A and B).
The modulating effect of 9d was specific to a target protein
present only on Ld39 because 9d did not have any modulating
effect on the SSG sensitivity of LdAG83 even when used up to
6 M (Fig. 6C).
We investigated the effect of 9d on the SSG accumulation of
L. donovani amastigotes. Axenic amastigotes were produced by
adapting the parasites to 37°C for 24 h. Light microscopy
showed that the cells have rounded up (data not shown). We
assumed that the parasites changed into the amastigote form.
Other researchers have demonstrated that this adaptation
method resulted in biochemical changes that were associated
with the amastigote formation (39).
In the SSG accumulation experiment, we used higher con-
centrations of 9d (30 and 60 M), together with a shorter
incubation time (3 h) to measure the SSG accumulation. In the
absence of 9d, the accumulations of SSG of Ld39 and Ld2001
were 28 and 15% of that of LdAG83, respectively (Fig. 6D).
When treated with 30 M 9d, the SSG accumulations of Ld39
and Ld2001 were increased to 74 and 83% of that of LdAG83,
respectively (Fig. 6D). When the concentration of 9d was fur-
ther increased to 60 M, the SSG accumulations of Ld39 and
Ld2001 were 90 and 69% of that of LdAG83, respectively (Fig.
6D). In contrast, the accumulation of SSG in SSG-sensitive
LdAG83 treated with 9d (30 or 60 M) did not significantly
differ from its accumulation in cells without any treatment,
indicating that the dimer 9d specifically inhibited the function
of the ABC transporters present only in an SSG-resistant strain
(Fig. 6D). Compound 9d did not have any cytotoxicity to L.
donovani at 60 M when treated for 3 h (data not shown),
confirming that the increase in SSG accumulation was due to
the modulating effect of 9d and not to its cytotoxic effect.
Comparison of the modulating activities of 9c and 9d with
other traditional MDR modulators. We compared the modu-
lating activities of 9c and 9d with verapamil, reserpine, quinine,
FIG. 4. Dose-dependent modulating activity of flavonoid dimers 9c
and 9d on the pentamidine resistance of LePentR50. LePentR50 pro-
mastigotes were seeded at 105 cells/well in 100 l and then incubated
at 27°C for 72 h with either flavonoid dimers only (9c only [A] or 9d
only [B]) or together with pentamidine (9c with 60 g of pentami-
dine/ml [A] or 9d with 60 g of pentamidine/ml [B]). The percentage
of survivors was measured by using an MTS assay. Each concentration
of 9c or 9d was tested in triplicate, and analyses were repeated three
times.
FIG. 5. Effect of 9d on pentamidine accumulation of LePentR50. A
1-ml portion of 4-day-old LePentR50 promastigotes (2  108 cells/ml)
was incubated at 27°C for 3 h with 0.84 mM pentamidine in the
presence of various concentrations of 9d (0, 15, 30, and 60 M). After
incubation, cells were washed with PBS, and the pentamidine concen-
tration was determined by HPLC. Each concentration of 9d was tested
in triplicate, and analyses were repeated twice.
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quinacrine, and quinidine. For LePentR50, the modulating
activities of modulators of 9c (IC50  47  1.2 g/ml) and 9d
(IC50  35  2.3 g/ml) were similar to those of reserpine
(IC50  40  1.3 g/ml) and quinacrine (IC50  28.7  1.3
g/ml), with about 2.7-, 3.7-, 3.2-, and 4.5-fold pentamidine
sensitizations, respectively (Fig. 7A). In contrast, only less than
a half-fold sensitization was demonstrated when verapamil,
quinine, and quinidine were used (Fig. 7A). Regarding the
modulating activity of SSG resistance in Ld39, only 9c and 9d
were effective (IC50  2.3  0.1 mg/ml and 1.8  0.05 mg/ml,
respectively), representing 3.1- and 3.9-fold SSG sensitization
(Fig. 7B). None of the other traditional MDR chemosensitizers
exhibited any modulating effect (IC50  7.2  0.54, 7.2  0.3,
7.0  0.21, 6.7  0.11, and 7.2  0.04 mg/ml for verapamil,
reserpine, quinine, quinacrine, and quinidine, respectively)
(Fig. 7B).
The target of the synthetic flavonoid dimers is not LeMDR1.
We are interested in identifying the target of the synthetic
flavonoid dimers. Other researchers have suggested that fla-
vonoid monomers can bind to the NBD of ABC transporter of
L. tropica (36). It is possible that our synthetic flavonoid dimers
will also bind to the ABC transporters via the two NBDs. We
have investigated whether the ABC transporter, LeMDR1, in
L. enriettii is the target of the synthetic flavonoid dimers. We
have previously demonstrated that LeMDR1 is an ABC trans-
porter that can mediate resistance to vinblastine and puromy-
cin and sensitivity to rhodamine 123 (11, 16). Here we studied
the modulating effect of the synthetic flavonoid dimers on
three L. enriettii cell lines, namely, wild-type Le, LeMDR1
knockout (LeMDR1/), and LeMDR1 overexpressed (LeV160).
We found that pentamidine resistance was inversely related to
the copy number of LeMDR1. The pentamidine IC50s for
LeMDR1/, Le wild type, and LeV160 are 18.9  0.8, 12.0 
0.8, and 9.0  0.1 g/ml, respectively (Table 2). When the
panel of synthetic flavonoid dimers was tested for their mod-
ulating activity on the pentamidine resistance of LeMDR1/,
we found that 9c and 9d were effective in reducing the IC50s of
pentamidine to 5  0.3 g/ml and 4.6  0.4 g/ml, respec-
tively, representing 3.8- and 4.1-fold sensitizations (Table 2).
Compounds 9b (IC50  9.4  0.4 g/ml) and 9 h-1 (IC50 
8.2 0.5 g/ml) showed 2.0- and 2.3-fold sensitizations, re-
spectively. However, 9a (IC50  18  1.0 g/ml), 9e (IC50 
FIG. 6. Dose-dependent modulating activity of 9c and 9d on the SSG resistance of Ld39. SSG-resistant Ld39 promastigotes were seeded at 105
cells/well in 100 l and incubated at 27°C for 72 h in the presence of serial dilutions of SSG and 9c (A) or 9d (B). The }, ■, Œ, , and ✳ symbols
represent 0, 1, 2, 4, and 6 M 9c or 9d, respectively. Wild-type LdAG83, without 9c, was included as control (). SSG-sensitive LdAG83
promastigotes were studied by using the same protocol as described above. (C) The percentage of survivors was quantified by using MTS assay
after 72 h of incubation at 27°C. Each datum point was tested in triplicate, and analyses were repeated three times in separate experiments. Note
that the concentration of SSG used for Ld39 is different from that of LdAG83. The effect of 9d on the SSG accumulation of LdAG83, Ld39, and
Ld2001 was studied in panel D. A 1-ml portion of 4-day-old axenic amastigotes at a cell density of 2  108 cells/ml was incubated at 37°C for 3 h
with 0.05 mM SSG and various concentrations of 9d (0, 30, or 60 M). After incubation, the cells were washed with PBS, and the total antimony
concentration was determined by ICP-MS. Each concentration of 9d was tested in triplicate, and analyses were repeated twice in separate
experiments. The total antimony concentration is presented as nmol per mg of protein (mean  standard error mean, n  2). The white bar, black
bar, and striped bar represent 0, 30, and 60 M 9d, respectively.
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12.5  0.1 g/ml), 9f (IC50  12.5  0.8 g/ml), 9i (IC50 
13.8 0.7 g/ml), 9j (IC50  20.9 1.3 g/ml), and 9k-1
(IC50  20.9  3 g/ml) gave less than half or no sensitization
effect (Table 2). When all of the flavonoid dimers were an-
alyzed, a “U”-shaped relationship was found between the
ethylene glycol linker length and the pentamidine resistance
modulating activity. This is similar to what we found in
LePentR50 (Fig. 3A).
In Le wild-type cells, 9d (IC50  4  0.3 g/ml) significantly
reduced the IC50 of pentamidine from 12.0  0.8 g/ml to
4.0 0.8 g/ml (3-fold decrease) (Table 2). In LeMDR1-
overexpressed LeV160, 9c (IC50  5.0  0.4 g/ml) and 9d
(IC50  4.7  0.1 g/ml) slightly decreased the IC50s of pent-
amidine from 9.0 0.1 g/ml to 5.0 0.4 and 4.7 0.1 g/ml,
respectively (approximately 1.8-fold and 1.9-fold decreases)
(Table 2). Compounds 9e (IC50  7.5  0.3 g/ml), 9f (IC50 
7.2  0.3 g/ml), and 9i (IC50  6.8  0.2 g/ml), however,
had no sensitization effect.
The observation that the synthetic flavonoid dimers can
modulate the pentamidine resistance irrespective of the copy
number of LeMDR1 suggests that LeMDR1 is not the target
for the synthetic flavonoid dimers. LeMDR1 is known to be
responsible for vinblastine and puromycin resistance in L.
enriettii (11, 16). When we tried to study the modulating activ-
ity of the flavonoid dimers on the vinblastine and puromycin
resistance of LeV160, we found that none of the flavonoid
dimers have any significant modulating activity (Table 2). This
result further confirms that our synthetic flavonoid dimers can-
not target LeMDR1.
DISCUSSION
Various ABC transporters in Leishmania have been impli-
cated in mediating drug resistance (38). These include Ldmdr1
in L. donovani (23), Lamdr1 and Lamdr2 in L. amazonensis
(21, 29), LtpgpA in L. tarentolae (20, 22, 33), Ltmdr1 in L.
tropica (19), Lemdr1 in L. enriettii (11), LmepgpA in L. mexi-
cana (13), LmpgpA in L. major (7), and PENr in L. major (12).
Structurally, they can be grouped into the ABCB (Ldmdr1,
Lamdr1, Lamdr2, Ltrmdr1, Lemdr1, and PENr) and ABCC
(LtpgpA, LmepgpA, and LmpgpA) types. Both ABCB and
ABCC transporters have two NBDs and therefore are poten-
tial targets of flavonoids. Indeed, flavonoids have been dem-
onstrated to modulate the daunomycin resistance in L. tropica
by binding to the NBDs of LtrMDR1 (36).
Success in overcoming MDR has been limited by a lack of
specificity and a low affinity of MDR modulators for the drug
binding sites of ABC transporter. An application of poly-
valency in drug design has recently been studied which exploits
the cooperativity effect during molecular recognition and bind-
ing, resulting in a polyvalent ligand binding more tightly than
equivalent monovalent system when the target protein has
multiple binding sites (10, 40, 42, 46). The existence of several
drug-binding sites in the homo- or -heterodimeric ABC trans-
porter suggests that polyvalency may be an invaluable ap-
TABLE 2. Effect of synthetic flavonoid dimers on pentamidine
resistance of LeMDR1 mutantsa
Compound
IC50 of pentamidine (g/ml)  SD
Mean IC50
(g/ml)  SD





No modulator 18.9  0.8 12.0  0.8 9.0  0.1 167.0  3.6 16.0  1.0
9a 18.0  1.0 ND ND 170.0  7.0 ND
9b 9.4  0.4 ND ND 160.0  6.0 ND
9c 5.0  0.3 ND 5.0  0.4 134.0  6.0 13.0  0.5
9d 4.6  0.4 4.0  0.3 4.7  0.1 140.0  2.3 15.0  0.6
9e 12.5  0.1 ND 7.5  0.3 170.0  2.3 19.0  0.4
9f 12.5  0.8 ND 7.2  0.3 165.0  2.3 17.0  1.0
9h-1 8.2  0.5 ND ND 160.0  8.0 ND
9i 13.8  0.7 ND 6.8  0.2 165.0  2.3 19.0  0.8
9j 20.9  1.3 ND ND 170.0  4.0 ND
9k-1 20.9  3.0 ND ND 150.0  6.0 ND
a The IC50 values for each drug were determined by a MTS-based proliferation
assay. Each IC50 value was derived from at least three independent experiments
with triplicates in each experiment. ND, not determined.
FIG. 7. Comparison of the modulating activity of 9c and 9d with
other MDR modulators on the pentamidine resistance of LePentR50
(A) and SSG resistance of Ld39 (B). Promastigotes were seeded at 105
cells/well in 100 l and incubated at 27°C for 72 h in the presence of
either 9c, 9d, or other traditional MDR modulators. All modulators
were used at the concentration of 6 M. The IC50 values were deter-
mined by using MTS assay. Each sample was tested in triplicate, and
analyses were repeated three times in separate experiments.
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proach to enhance the efficacy of MDR modulators. In the
present study, we used dimers of flavonoids that differ only in
the length of ethylene glycol (from one ethylene glycol unit to
thirteen ethylene glycol units) to investigate whether poly-
valency is a practical strategy to develop inhibitors for the ABC
transporter-mediated pentamidine and SSG resistance in the
parasite Leishmania.
Pentamidine resistance in Leishmania may be caused by the
exclusion of pentamidine from mitochondria in L. mexicana
(3) and in L. donovani (32). A genetic approach has identified
an ABC transporter PRP1 that may be involved in pentami-
dine resistance (12). It is possible that multiple factors are
involved in pentamidine resistance. Here we have used a
stepwise selected pentamidine-resistant L. enriettii cell line
(LePentR50) to investigate the molecular mechanism of pent-
amidine resistance. First, the pentamidine resistance factor
may be an ABC transporter because our synthetic flavonoid
dimer, particularly 9c and 9d, can modulate the pentamidine
resistance of LePentR50 in a dose-dependent manner. Fla-
vonoids have been demonstrated to be an efficient MDR mod-
ulator in both mammalian P-gp (15) and Leishmania ABC
transporters (36) by binding to the NBDs. We assume that our
synthetic apigenin dimers may also bind to the NBDs, although
we do not have any direct proof yet. We have previously dem-
onstrated that our synthetic flavonoid dimers can inhibit P-gp-
mediated anticancer drug resistance in mammalian cells by
increasing drug accumulation (8). Such observations support
our hypothesis that our synthetic flavonoid dimers might in-
deed bind to a putative ABC transporter in Leishmania. Sec-
ond, this putative ABC transporter is not LeMDR1 because
our flavonoid dimers can modulate the pentamidine resistance
irrespective of the LeMDR1 copy number (LeMDR1/, Le, or
LeV160). This is further confirmed by the observation that the
LeMDR1-mediated vinblastine and puromycin resistance are
not affected by the flavonoid dimers. The identity of this ABC
transporter remains elusive. In addition to this ABC trans-
porter, there may be other factors that might contribute to
pentamidine resistance in L. enriettii. LeMDR1 could be one of
the factors. Here we found that pentamidine resistance is in-
versely associated with LeMDR1 copy number. The IC50 of
pentamidine of LeMDR1/, Le, and LeV160 are 18.9  0.8,
12.0  0.8, and 9.0  0.1 g/ml, respectively (Table 2). We
have previously reported that LeMDR1 is inversely associated
with rhodamine resistance, and LeMDR1 may be sequestering
to a multivesicular tubules that could connect to mitochondria
(16). Therefore, LeMDR1 overexpression results in concen-
trating rhodamine 123 with its mitochondrial target and causes
hypersensitivity. Based on our observation here, we hypothe-
size that LeMDR1 may be working similarly on causing pent-
amidine hypersensitivity by concentrating pentamidine with its
mitochondrial target(s). In such a case, LeMDR1 may be the
factor involved in the accumulation of pentamidine indirectly
into mitochondria. In summary, we hypothesize that the pent-
amidine resistance in L. enriettii may be caused by an ABC
transporter involved in lowering pentamidine accumulation. In
addition, LeMDR1 is involved in importing pentamidine indi-
rectly into mitochondria, possibly via multivesicular tubules.
Regardless of the identity of the putative ABC transporter
that causes pentamidine resistance in LePentR50, our syn-
thetic flavonoid dimers can inhibit it and reverse the pentam-
idine resistance. Compounds 9c or 9d with two apigenins con-
nected by three or four ethylene glycol units exhibited the
highest modulating activity of both pentamidine and SSG re-
sistance, with an 3-fold decrease in IC50. Other flavonoid
dimers with longer or shorter linker lengths showed a lower
activity or no modulating activity. The apigenin monomers
with the same number of ethylene glycols in the linker (10a and
10b) did not have any modulating activity, even when twice the
concentration was used (12 M). This clearly demonstrates
that the modulatory activity of 9c and 9d is not due to the
doubled concentration of the flavonoid binding to the ABC
transporters but rather due to the chain length effect of the
ethylene glycol units between the two apigenins. The optimal
chain length is three to four ethylene glycol units. This result
suggests that the two apigenin targets of the transporter have
a relatively optimal distance between them. Only when the
flavonoid dimers have the suitable length (three to four ethyl-
ene glycol units) will they be able to bind to them tightly.
Previously, we have reported that the optimal linker length to
modulate paclitaxel resistance in human breast cancer cells was
also three to four ethylene glycols, suggesting the transporter
in L. enriettii and L. donovani involved in pentamidine and SSG
resistance is likely to be an ABC transporter and may have a
similar structure as the human P-gp (8). The distance between
the two apigenin targets will have a similar distance between
them.
9c and 9d work to reverse the pentamidine and SSG resis-
tance by increasing drug accumulation in the resistant cells.
Treatment with 9c and 9d resulted in a dose-dependent in-
crease in the accumulation of pentamidine and SSG. This
result also indirectly suggests that an efflux transporter is me-
diating pentamidine and SSG resistance by lowering the drug
accumulation. We are assuming that such an efflux transporter
is an ABC transporter and that it is the target of 9c and 9d. At
this point, we do not know where the flavonoid dimers are
binding to the putative ABC transporter. Flavonoids have been
demonstrated to bind to a region that is overlapped by the
ATP-binding and the steroid-binding region. However, we
have no experimental evidence to show that the flavonoid
dimer is binding to the same site at which the monomer binds.
The target could either be the NBD or the drug binding site. In
the former case, the flavonoid dimer will inhibit the ATPase
activity, whereas in the latter case the flavonoid dimer will act
as a competitive inhibitor.
In comparison with other traditional MDR modulators, 9c
and 9d exhibited a pentamidine resistance reversal activity
comparable to that of reserpine and quinacrine. In the case of
SSG resistance, only 9c and 9d have significant modulating
activity, whereas none of the traditional MDR modulators
work. This demonstrates that polyvalency is indeed a powerful
approach in designing novel MDR modulators. An application
of polyvalency in drug design has recently been studied that
exploits the cooperativity effect in molecular recognition and
binding (10, 40, 42, 46). Our study now demonstrates that the
bivalent nature of flavonoid synthesized in the present study
can dramatically increase the reversal activity of modulators, so
it is of great significance for future clinical application.
In summary, our study demonstrates that dimerization of
flavonoids using spacers of a defined ethylene glycol units can
enhance the reversal activity of modulators on antileishmanial
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drug resistance. The flavonoid dimers with three or four eth-
ylene glycol units (9c or 9d) displayed the greatest modulatory
activity, with 3-fold sensitizations of pentamidine and SSG
resistance, respectively, and in a dose-dependent manner.
Moreover, their reversal activity on antileishmanial drug resis-
tance was explained by the increase in intracellular accumula-
tion of pentamidine and total antimony. Although the present
study demonstrates that flavonoid dimers are effective modu-
lators in vitro, animal experiments are required to determine
whether the flavonoid dimers have the potential to be devel-
oped as an effective chemosensitizer for inhibiting pentamidine
and SSG resistance in Leishmania.
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